Findings

What do systematic reviews say?

9 questions · 9 findings · 1 reviews · Colorectal

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 11.1%Moderate 3 · 33.3%High 5 · 55.6%

Overall survival · people with metastatic colorectal cancer ‐ KRAS exon 2 MT

The intervention showed no clear difference in overall survival (high certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.03 [0.94, 1.13]
8 studies · 2268 participants
High

Overall survival · people with metastatic colorectal cancer ‐ extended RAS WT

The intervention leads to lower overall survival (high certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.77 [0.67, 0.88]
4 studies · 1053 participants
High

Overall survival · people with metastatic colorectal cancer ‐ KRAS exon 2 WT

The intervention leads to lower overall survival (high certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.88 [0.8, 0.98]
12 studies · 4249 participants
High

Overall survival · people with metastatic colorectal cancer ‐ extended RAS MT

The intervention showed no clear difference in overall survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.09 [0.93, 1.28]
4 studies · 1768 participants
Moderate

Overall survival · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1382 participants
High

Overall survival · people with metastatic colorectal cancer

The intervention showed no clear difference in overall survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.84 [0.7, 1.01]
4 studies · 2189 participants
Moderate

Overall survival · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1482 participants
High

Overall survival · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 99 participants
Moderate

Overall survival · people with metastatic colorectal cancer

The intervention showed no clear difference in overall survival (low certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1 [0.69, 1.47]
5 studies · 1257 participants
Low